Evidence map›Paper›PMID 33569721›Full record

ArticleJournal of endocrinological investigation2021

Evaluation of

K B Daniel, A de Oliveira Santos, R A de Andrade, M B F Trentin, H M Garmes

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
    Review
  2. Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

K B DanielDivision of Endocrinology, Clinical Medicine Department, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Camargo, 126, Campinas, São Paulo, 13084-971, Brazil. ka_borgesdaniel@hotmail.com.ORCID http://orcid.org/0000-0002-4247-5819
A de Oliveira SantosDivision of Nuclear Medicine, Radiology Department, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil.
R A de AndradeDivision of Nuclear Medicine, Radiology Department, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil.
M B F TrentinDivision of Endocrinology, Clinical Medicine Department, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Camargo, 126, Campinas, São Paulo, 13084-971, Brazil.
H M GarmesDivision of Endocrinology, Clinical Medicine Department, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Camargo, 126, Campinas, São Paulo, 13084-971, Brazil. heraldomg@uol.com.br.ORCID http://orcid.org/0000-0001-6117-8548
Universidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcromegaly is associated with many comorbidities and increased mortality. The first-line treatment is transsphenoidal surgery. However, many patients also need adjuvant drug treatment after surgery. Somatostatin analog (SSA), which suppresses GH secretion by somatotrophs by binding to the SSTR2 receptor, is the first choice. Nevertheless, 50% of patients are partially or totally resistant to SSA, so predictive factors of response are helpful to individualize drug treatment.

methodsFifteen acromegalics patients on SSA treatment for at least 6 months were underwent to

resultsAs a result, we did not find out a significantly higher SUV max in the complete response group (p = 0.0576) to SSA. However, we found a significant inverse relationship between postoperative GH values and the SUVmax at the sella turcica (p = 0.0188), probably reflecting tumor SSTR2 expression.

conclusionThus, after this initial evaluation,

Indexed as

AcromegalyAdultAgedCross-Sectional StudiesFemaleFollow-Up StudiesHormonesHumansMaleMiddle AgedOrganometallic CompoundsPituitary NeoplasmsPositron Emission Tomography Computed TomographyPrognosisSomatostatinYoung Adultgallium Ga 68 dotatateHormonesOrganometallic CompoundsSomatostatin68Ga-DOTATATEAcromegalySomatostatin analogsSSTR2

Identifiers

PMID33569721
OpenAlexW3126363370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.